About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

82.94 -1.35 (-1.60%)

Streaming Delayed Price Updated: 9:45 AM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

October 02, 2023

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗

September 29, 2023

Via Benzinga

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

September 27, 2023

Via Benzinga

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

June 07, 2023

Via Benzinga

Recap: Ionis Pharmaceuticals Q1 Earnings ↗

May 03, 2023

Via Benzinga

Ionis Pharmaceuticals's Earnings Outlook ↗

May 02, 2023

Via Benzinga

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY

Via Benzinga

Why Ionis Pharmaceuticals Stock Popped Today ↗

September 26, 2023

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met the primary endpoint with a statistically significant...

Via Benzinga

Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action ↗

September 26, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a hereditary disease that prevents...

Via Benzinga

Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder ↗

September 26, 2023

IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.

Via Investor's Business Daily

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Highlighted for Surprising Price Action

September 26, 2023

Via Investor Brand Network

The 7 Most Hated Stocks by Institutional Traders ↗

September 20, 2023

Discover the surprising stocks institutional traders are selling, and find out what their moves could mean for your portfolio's future.

Via InvestorPlace

Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope ↗

September 07, 2023

Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,

Via Benzinga

Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports ↗

August 07, 2023

Via Benzinga

Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook ↗

July 31, 2023

Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 ↗

July 31, 2023

Via Benzinga

Apple To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Monday ↗

July 31, 2023

Keybanc cut the price target for Baxter International Inc. (NYSE: BAX) from $53 to $51. Keybanc analyst Matthew Mishan maintained an Overweight rating. Baxter International shares rose 1.2% to $47.58...

Via Benzinga

BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease ↗

July 17, 2023

The companies are working on treatments for a leading cause of heart failure.

Via Investor's Business Daily

Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment ↗

July 03, 2023

Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting

Via Benzinga

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

June 30, 2023

From Biogen Inc.

Via GlobeNewswire

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million ↗

June 15, 2023

Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.

Via Investor's Business Daily

Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst ↗

June 12, 2023

Sunday, Intellia Therapeutics Inc (NASDAQ: NTLA) announced updated interim results from the Phase 1 portion of the ongoing

Via Benzinga

Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway' ↗

June 07, 2023

Piper Sandler assumed coverage of Ionis Pharmaceuticals Inc (NASDAQ: IONS) with an Overweight rating and a

Via Benzinga

Why Ionis Pharmaceutical Shares Are Trading Lower Wednesday ↗

June 07, 2023

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading lower on Wednesday after the company announced plans to offer $500 million of senior convertible notes due in 2028 in a private placement...

Via Benzinga

Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79 ↗

May 24, 2023

The Relative Strength Rating for Ionis Pharmaceuticals stock moved into a new percentile Wednesday, as it got a lift from 65 to 79.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗

May 04, 2023

Via Benzinga

Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA ↗

April 26, 2023

The FDA approved Biogen Inc's (NASDAQ:

Via Benzinga

What's Going On With Biogen Stock Tuesday? ↗

April 25, 2023

Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.

Via Benzinga

Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs ↗

April 25, 2023

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

All News about Ionis Pharmaceuticals, Inc. - Common Stock

Sections

Services

Contact Information

Follow Us